MA40765A - Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine - Google Patents

Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine

Info

Publication number
MA40765A
MA40765A MA040765A MA40765A MA40765A MA 40765 A MA40765 A MA 40765A MA 040765 A MA040765 A MA 040765A MA 40765 A MA40765 A MA 40765A MA 40765 A MA40765 A MA 40765A
Authority
MA
Morocco
Prior art keywords
immunity against
protective immunity
methods
immunodeficiency virus
human immunodeficiency
Prior art date
Application number
MA040765A
Other languages
English (en)
Other versions
MA40765B1 (fr
Inventor
Dan Barouch
Jennifer Anne Hendriks
Maria Grazia Pau
Johanna Schuitemaker
Frank Tomaka
Manen Danielle Van
Original Assignee
Beth Israel Deaconess Medical Ct Inc
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Ct Inc, Janssen Vaccines & Prevention Bv filed Critical Beth Israel Deaconess Medical Ct Inc
Publication of MA40765A publication Critical patent/MA40765A/fr
Publication of MA40765B1 publication Critical patent/MA40765B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

L'invention concerne des compositions, des vaccins et des méthodes permettant d'induire une immunité protectrice vis-à-vis de l'infection à vih (virus de l'immunodéficience humaine). Des associations de vaccins hétérologues d'un ou plusieurs vecteurs d'expression virale et un polypeptide antigénique isolé induisent une forte immunité protectrice vis-à-vis d'infections par un ou plusieurs clades du vih.
MA40765A 2014-09-26 2015-09-24 Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine MA40765B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462056059P 2014-09-26 2014-09-26
PCT/US2015/051891 WO2016049287A1 (fr) 2014-09-26 2015-09-24 Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine

Publications (2)

Publication Number Publication Date
MA40765A true MA40765A (fr) 2017-08-02
MA40765B1 MA40765B1 (fr) 2021-04-30

Family

ID=55581992

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40765A MA40765B1 (fr) 2014-09-26 2015-09-24 Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine

Country Status (28)

Country Link
US (4) US10137191B2 (fr)
EP (2) EP3868398A1 (fr)
JP (2) JP6438575B2 (fr)
KR (2) KR101971808B1 (fr)
CN (2) CN112121160A (fr)
AP (1) AP2017009846A0 (fr)
AU (2) AU2015320574B2 (fr)
BR (1) BR112017005917A2 (fr)
CA (1) CA2961024A1 (fr)
CY (1) CY1124254T1 (fr)
DK (1) DK3197489T3 (fr)
EA (2) EA202092521A1 (fr)
ES (1) ES2865150T3 (fr)
HR (1) HRP20210608T1 (fr)
HU (1) HUE053585T2 (fr)
IL (2) IL251114B (fr)
LT (1) LT3197489T (fr)
MA (1) MA40765B1 (fr)
MX (2) MX2017003946A (fr)
MY (1) MY175620A (fr)
PH (1) PH12017500449A1 (fr)
PL (1) PL3197489T3 (fr)
PT (1) PT3197489T (fr)
RS (1) RS61902B1 (fr)
SG (1) SG11201702110RA (fr)
SI (1) SI3197489T1 (fr)
WO (1) WO2016049287A1 (fr)
ZA (1) ZA201702053B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61902B1 (sr) * 2014-09-26 2021-06-30 Beth Israel Deaconess Medical Ct Inc Metodi i kompozicije za indukovanje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
AU2016369326B2 (en) 2015-12-15 2019-02-21 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
US11098086B2 (en) 2016-02-16 2021-08-24 Geovax Inc. Multivalent HIV vaccine boost compositions and methods of use
US10273268B2 (en) 2016-06-16 2019-04-30 Janssen Vaccines & Prevention B.V. HIV vaccine formulation
AU2017318689A1 (en) * 2016-09-02 2019-04-11 Beth Israel Deaconess Medical Center, Inc. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
HUE052008T2 (hu) 2016-09-15 2021-04-28 Janssen Vaccines & Prevention Bv Trimert stabilizáló HIV-burokfehérje-mutációk
MA49397A (fr) 2017-06-15 2020-04-22 Bavarian Nordic As Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation
BR112020000867A2 (pt) 2017-07-19 2020-07-21 Janssen Vaccines & Prevention B.V. mutações da proteína do envelope do hiv estabilizando o trímero
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
WO2019055888A1 (fr) * 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Méthodes pour induire une réponse immunitaire contre une infection par le virus de l'immunodéficience humaine chez des sujets subissant un traitement antirétroviral
WO2020064621A1 (fr) 2018-09-25 2020-04-02 Janssen Vaccines & Prevention B.V. Méthode d'induction d'une réponse immunitaire contre le virus de l'immunodéficience humaine par administration co-localisée de composants vaccinaux
CN114269363A (zh) * 2019-04-17 2022-04-01 威斯达研究所 用于hiv疫苗应用的复制缺陷型腺病毒载体
TW202110476A (zh) * 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
EP3972642A1 (fr) * 2019-05-22 2022-03-30 Aelix Therapeutics S.L. Régimes posologiques pour vaccins
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
IL292760A (en) * 2019-11-07 2022-07-01 Janssen Vaccines Prevention B V Purification of proteins
WO2023198815A1 (fr) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Administration séquentielle d'adénovirus

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (fr) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Virus recombinant de la vaccine derive du virus modifie ankara
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
ATE519854T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus auf basis von serotyp 48 (ad48).
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
EP1214333A4 (fr) 1999-09-17 2005-01-19 Dana Farber Cancer Inst Inc Trimeres stabilises solubles de glycoproteines
NZ524661A (en) 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
WO2003004657A1 (fr) 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
CA2466413C (fr) 2001-12-04 2014-11-04 Bavarian Nordic A/S Vaccin a sous-unite de ns1 de flavivirus
CA2478508C (fr) 2002-04-25 2013-07-02 Crucell Holland B.V. Vecteurs adenoviraux stables et techniques de propagation de ces vecteurs
CA2477954C (fr) 2002-04-25 2012-07-10 Crucell Holland B.V. Moyens et procede de production de vecteurs d'adenovirus
AU2003291402A1 (en) 2002-11-07 2004-06-03 Beth Israel Deaconess Medical Center MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
WO2004050856A2 (fr) 2002-12-03 2004-06-17 University Of Massachusetts Vaccins a adn polyvalents contre la glycoproteine du vih-1 primaire et procedes de vaccination
EP2359851A3 (fr) 2003-03-28 2011-08-31 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services MVA exprimant des gènes enveloppe, gag et pol du vih
CA2539021A1 (fr) * 2003-09-15 2005-03-31 Chiron Corporation Approches combinees pour produire des reponses immunitaires
US20070298051A1 (en) 2003-11-19 2007-12-27 Beth Israel Deaconess Medical Center Adjuvants Of Immune Response
CA2553541C (fr) 2004-01-23 2015-04-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Porteurs de vaccin adenoviral de chimpanze
US20080274134A1 (en) 2004-06-15 2008-11-06 Norbert Schulke Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex
JP4772045B2 (ja) 2004-07-16 2011-09-14 アメリカ合衆国 Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン
AU2005279799A1 (en) 2004-08-27 2006-03-09 Emory University Recombinant MVA viruses expressing Clade A/G, Clade B and Clade C modified HIV ENV, GAG and POL genes
AP2351A (en) 2004-10-13 2012-01-25 Crucell Holland Bv Improved adenoviral vectors and uses thereof.
US20100015211A1 (en) * 2004-11-01 2010-01-21 Barnett Susan W Combination Approaches For Generating Immune Responses
WO2007005934A2 (fr) 2005-07-06 2007-01-11 University Of Maryland Biotechnology Institute Immunogene a base d'enveloppe de vih de type limite presentant simultanement des sites de liaison de recepteur et de co-recepteur
EP1917040A4 (fr) 2005-08-23 2012-12-12 Univ California Vaccin polyvalent
WO2007104792A2 (fr) 2006-03-16 2007-09-20 Crucell Holland B.V. Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci
EP2040747A4 (fr) 2006-06-19 2010-08-25 Progenics Pharm Inc Protéines env vih trimériques solubles stabilisées et leurs utilisations
CA2667358A1 (fr) 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Polypeptides d'enveloppe gp140 modifies en provenance d'isolats du vih-1, compositions, complexes trimeriques et utilisations de ceux-ci
US20080279879A1 (en) 2006-11-17 2008-11-13 New York University INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
EP2137210B1 (fr) 2007-03-02 2016-10-19 GlaxoSmithKline Biologicals SA Nouveau procédé et nouvelles compositions
LT3335728T (lt) 2008-10-10 2020-03-10 Children`S Medical Center Corporation Biocheminiu požiūriu stabilizuota živ-1 env trimero vakcina
WO2010059732A1 (fr) 2008-11-18 2010-05-27 Beth Israel Deaconess Medical Center Vaccins antiviraux présentant une immunogénicité cellulaire améliorée
WO2010085984A1 (fr) 2009-02-02 2010-08-05 Okairos Ag Séquences d'acide nucléique et d'acides aminés d'adénovirus simiens, vecteurs les contenant et leurs utilisations
JP5882741B2 (ja) 2009-02-02 2016-03-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サルアデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用
WO2010096561A1 (fr) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines gag du vih/vis de synthèse et leurs utilisations
CN105399833B (zh) 2010-01-04 2019-09-06 Kj 生物科学有限公司 用于疫苗和诊断学的Dps融合蛋白
AU2011209175B2 (en) 2010-01-28 2016-02-04 Bavarian Nordic A/S Vaccinia virus mutants containing the major genomic deletions of MVA
AU2011214262B2 (en) * 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
EP3556396B1 (fr) 2010-08-31 2022-04-20 Theraclone Sciences, Inc. Anticorps de neutralisation du virus de l'immunodéficience humaine (vih)
US9173933B2 (en) 2010-10-15 2015-11-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara influenza vaccine
US9701718B2 (en) * 2010-12-14 2017-07-11 Janssen Vaccines & Prevention B.V. Adenovirus serotype 26 and serotype 35 filovirus vaccines
US20140348791A1 (en) 2011-09-09 2014-11-27 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2766037A4 (fr) 2011-10-12 2015-08-05 Scripps Research Inst Mini boucle v3 de gp120 du vih-1 et ses utilisations
US9683268B2 (en) 2012-09-19 2017-06-20 Beth Israel Deaconess Viruses associated with immunodeficiency and enteropathy and methods using same
CA3200425A1 (fr) 2012-11-16 2014-05-22 Peter ABBINK Adenovirus recombinants et leur utilisation
SG11201505229XA (en) * 2013-01-07 2015-08-28 Beth Israel Hospital Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
WO2014124301A1 (fr) 2013-02-07 2014-08-14 University Of Washington Through Its Center For Commercialization Nanostructures protéiques à auto-assemblage
WO2015048770A2 (fr) 2013-09-30 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Traitements par anticorps pour le virus de l'immunodéficience humaine (vih)
CN103992396B (zh) * 2014-04-17 2017-03-29 南开大学 一种潜在的高效重组HIV‑1 CRF07‑BC gp140免疫原的制备方法
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
RS61902B1 (sr) * 2014-09-26 2021-06-30 Beth Israel Deaconess Medical Ct Inc Metodi i kompozicije za indukovanje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
AU2016369326B2 (en) 2015-12-15 2019-02-21 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
AU2017318689A1 (en) * 2016-09-02 2019-04-11 Beth Israel Deaconess Medical Center, Inc. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment

Also Published As

Publication number Publication date
PT3197489T (pt) 2021-04-30
AU2015320574A1 (en) 2017-04-06
EP3197489B1 (fr) 2021-02-17
CN106999571A (zh) 2017-08-01
PL3197489T3 (pl) 2021-11-08
SI3197489T1 (sl) 2021-08-31
MY175620A (en) 2020-07-02
JP6438575B2 (ja) 2018-12-12
JP6625716B2 (ja) 2019-12-25
DK3197489T3 (da) 2021-04-19
US20220096622A1 (en) 2022-03-31
US10137191B2 (en) 2018-11-27
WO2016049287A1 (fr) 2016-03-31
AU2015320574B2 (en) 2018-12-06
RS61902B1 (sr) 2021-06-30
SG11201702110RA (en) 2017-04-27
LT3197489T (lt) 2021-07-26
AP2017009846A0 (en) 2017-03-31
EA201790717A1 (ru) 2018-02-28
CA2961024A1 (fr) 2016-03-31
IL265733A (en) 2019-05-30
EP3197489A4 (fr) 2018-03-14
JP2017531627A (ja) 2017-10-26
ZA201702053B (en) 2021-09-29
KR102159626B1 (ko) 2020-09-25
IL265733B (en) 2021-05-31
HRP20210608T1 (hr) 2021-06-11
US10471137B2 (en) 2019-11-12
NZ730841A (en) 2021-08-27
US20180250385A1 (en) 2018-09-06
US20200030437A1 (en) 2020-01-30
CN112121160A (zh) 2020-12-25
EA037583B1 (ru) 2021-04-16
IL251114B (en) 2019-05-30
MX2020013153A (es) 2021-02-18
AU2018267669B2 (en) 2020-03-05
BR112017005917A2 (pt) 2017-12-12
PH12017500449A1 (en) 2017-07-31
MX2017003946A (es) 2017-12-20
ES2865150T3 (es) 2021-10-15
EA202092521A1 (ru) 2021-05-31
CY1124254T1 (el) 2022-07-22
MA40765B1 (fr) 2021-04-30
EP3868398A1 (fr) 2021-08-25
US20160089432A1 (en) 2016-03-31
KR20190042736A (ko) 2019-04-24
CN106999571B (zh) 2020-10-02
AU2018267669A1 (en) 2018-12-13
KR20170066454A (ko) 2017-06-14
HUE053585T2 (hu) 2021-07-28
US11207400B2 (en) 2021-12-28
JP2019038849A (ja) 2019-03-14
EP3197489A1 (fr) 2017-08-02
KR101971808B1 (ko) 2019-04-23
IL251114A0 (en) 2017-04-30

Similar Documents

Publication Publication Date Title
MA40765A (fr) Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
MX2018005569A (es) Vacunas contra el virus de la hepatitis b.
EA202092808A1 (ru) Вакцины на основе наночастиц с новыми структурными компонентами
EP4233898A3 (fr) Vaccins contre l'arnm de la grippe
EA201790532A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201691993A1 (ru) Вакцина к вирусу эпидемической диареи свиней
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
WO2015134368A3 (fr) Vecteurs de vaccin du virus de l'herpès simplex 2 (vhs -2) de recombinaison(hsv -2)
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
MX2019004593A (es) Vectores recombinantes que expresan antigenos de virus de influenza aviar y usos de los mismos.
CO2018008288A2 (es) Virus de la tilapia de tipo ortomixo
MX2018006416A (es) Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina.
EA201890042A1 (ru) Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
MX2022016066A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
EA201990719A1 (ru) Новые промоторы
AU2015364253B2 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
EA202191862A2 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
EA201892488A1 (ru) Комбинации лечебных вакцин против впч